Betrixaban is a new, long-acting, oral and selective Factor Xa inhibitor that decreases prothrombinase activity and thrombin generation.

 

Brand: BCM

 

Target: Factor Xa

 

Signaling Pathways: Metabolism

 

In Vitro: In patch clamp hERG assays, Betrixaban has IC50 of 8.9 μM. The plasma kallikrein IC50 and Ki values for Betrixaban are 6.3 μM and 3.5 μM respectively. Betrixaban (hERG Ki 1.8 μM) exhibits significantly lower hERG activity than all the others (hERG Ki?0.5 μM).

 

Melting Point: 210-213°C

 

pKa: 11.00±0.70(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water; Insoluble in Ethanol.

 

GHS: GHS07, GHS08

 

Isomeric SMILES: CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl  

 

InChIKey: XHOLNRLADUSQLD-UHFFFAOYSA-N  

 

InChI: InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31)

 

Attribute
[Chem Name]	N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide
[Synonym]	Betrixaban
[CAS No.]	330942-05-7
[EINECS]	682-459-2
[MDL No.]	MFCD16038040
[Formula]	C23H22ClN5O3
[Molecular]	451.91
[Form]	Off-White Solid
[Storage]	Sealed in dry, 2-8°C

Goods Tag